EWTX - Edgewise Therapeutics posts topline results from early-stage EDG-5506 trial

Edgewise Therapeutics (NASDAQ:EWTX) posts topline results from the company's early-stage study of EDG-5506. EDG-5506 is an orally administered small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Pharmacokinetic (PK) data showed robust target engagement with achievement of muscle concentrations well above efficacious levels observed in preclinical disease models, the company said. Pharmacodynamic (PD) data demonstrated dose proportionate effect on involuntary twitch inhibition in healthy volunteers. Edgewise also said that the Phase 1a single ascending dose/MAD package supports the initiation of Phase 2 trials in BMD and DMD in 2022. EDG-5506 was generally well tolerated with no serious adverse events observed to date.

For further details see:

Edgewise Therapeutics posts topline results from early-stage EDG-5506 trial